Klotho vs P-21 Peptide
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Klotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profileP-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profile| Klotho | P-21 Peptide | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) |
| Administration | Intravenous (research), Subcutaneous injection | Intranasal, Subcutaneous injection |
| Key side effects | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Klotho is research-stage, while P-21 Peptide is preclinical only.
- Administration: Klotho — Intravenous (research), Subcutaneous injection; P-21 Peptide — Intranasal, Subcutaneous injection.
- Dosing units differ: Klotho is dosed in mcg/kg, P-21 Peptide in mcg — they operate at different scales.
- Frequency: Klotho is typically every 3–7 days IV or SC (research); P-21 Peptide is daily or every other day (intranasal or SC).
How each works
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.